Article
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases - 1 Jul 2017
Boglione Lucio, Cardellino Chiara Simona, Cusato Jessica, De Nicolò Amedeo, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio
Abstract excerpt
The new direct-acting antivirals agents (DAAs) rapidly changed the treatment approach in chronic hepatitis C (CHC); however, the interferon (IFN)-free therapies availability is currently different in some countries, due to higher costs of these drugs. Naïve treated patients, who are not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated (PEG)-IFN and ribavirin (RBV),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.